Skip to main content
Caplight Logo









Hangzhou Shangjian Biotechnology Co., Ltd.

Hangzhou Shangjian Biotechnology Co., Ltd.

Private
HangzhouHealthcare & Life Scienceshttps://shangjianpharma.com

Last Round

Series B

Extension

Dec 30, 2021

Total Funding Raised

$32.34M

Company Overview

Hangzhou Shangjian Biotechnology Co., Ltd. is a biopharmaceutical company focused on the research and development of novel antibody therapeutics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

antibody therapeuticsmonoclonal antibodiesantibody-drug conjugatesADCbispecific antibodiesbiologicsoncologyimmunologydrug discoveryclinical-stage biotechbiotech startuphematologic malignanciesautoimmune diseasesdrug licensingAI-driven drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hangzhou Shangjian Biotechnology Co., Ltd. Comparables

Compare Hangzhou Shangjian Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.

Hangzhou Shangjian Biotechnology Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TJ Biopharma
87%
CASI Pharmaceuticals
79%
Johnson & Johnson
73%

Hangzhou Shangjian Biotechnology Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionDec 30, 2021
Series BSep 15, 2020
Series A ExtensionJan 1, 2019
Series AJun 1, 2018
AngelMar 1, 2017

Hangzhou Shangjian Biotechnology Co., Ltd. Investors

Notable investors and investment history

Hangzhou Shangjian Biotechnology Co., Ltd. investors
InvestorRounds
Zheshang Venture CapitalSeries B Extension
Zhejiang Sino Wisdom Investment ManagementSeries B
BOCOM International Holdings Company LimitedSeries B
Addor CapitalSeries B Extension, Series B
Hankang CapitalSeries B Extension, Series A
Cowin CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 15, 2020

    $32M round led by Addor Capital, Cowin Capital, and Zhejiang Sino Wisdom.

  • Jun 1, 2018

    Hankang Capital led the Series A round.

Hangzhou Shangjian Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hangzhou Shangjian Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hangzhou Shangjian Biotechnology Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Year FoundedN/A
Last FundingDec 30, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?